HOME >> BIOLOGY >> NEWS
Research sheds light on how cancer cells become resistant to treatment

A new study by researchers at Memorial Sloan-Kettering Cancer Center and The Johns Hopkins University provides new insight into how tumor cells can become resistant to anti-cancer therapy.

The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro. According to the authors, the research is the first to demonstrate that a protein transferred between cells retains its function long enough to allow the recipient cells to survive potentially toxic drug concentrations and ultimately develop intrinsic resistance.

In other words, cells that would normally be sensitive to treatment can develop resistance to it by receiving P-glycoprotein from other cells, making chemotherapy much less efficient. Uncovering the mechanism of this unusual "jumping" of the protein between the cells can potentially improve treatment success.

The authors conclude that their findings offer a new way in which to look at how cells behave in a community of cells within a tumor mass. The results have important implications for genomic analyses within tumor samples because resistance to cancer therapy can be achieved by protein transfer alone.

The new research will be published the week of January 17, 2005 in the online Early Edition of the Proceedings of the National Academy of Sciences (PNAS).


'"/>

Contact: Esther Carver
carvere@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
17-Jan-2005


Page: 1

Related biology news :

1. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
2. Research shows skeleton to be endocrine organ
3. Research aims to identify markers for menopausal women at risk for deadly blood clot
4. Research team enlightens the reasons for severe blindness
5. Research teams uncover risk genes for multiple sclerosis
6. Research shows NPD1 protects a key component of vision
7. Researchers find pathway that controls cell size and division
8. Researchers watch antibiotics, bacteria meet at atomic level
9. Researchers discover gene responsible for Restless Legs Syndrome
10. Research study describes the role part of the brain plays in memory
11. NY Stem Cell Foundations 2nd Annual Translational Stem Cell Research Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/3/2018)... ... October 03, 2018 , ... Fit4D, ... the appointment of healthcare visionary, Jimmy Lee, as Strategic Advisor to the company’s ... of healthcare industry experience. As a Senior Executive at Anthem, he had P&L ...
(Date:10/2/2018)... ... ... a fun-loving eight-year-old Labrador retriever. Like many labs, Stuart’s favorite thing in the world ... much that whenever anyone comes to our door, he grabs a toy to greet them, ... 2017, Stuart began limping and eventually could no longer play fetch. Though he was ...
(Date:10/2/2018)... ... October 02, 2018 , ... As a leading ... Biosciences, The Cell Analysis Company , is excited to offer xCELLigence® RTCA ... design and data analysis for immune oncology researchers are now much easier, especially ...
Breaking Biology News(10 mins):
(Date:9/29/2018)... ... September 29, 2018 , ... Voxx ... early-stage companies to access the power of influence analytics and data-driven engagement decision ... a broader market that didn’t necessarily have access to the same financial resources ...
(Date:9/27/2018)... ... 2018 , ... Medable was named DPharm Idol at this ... human digitome, a digital representation of human health and disease, by removing the ... data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, explained that their ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s ... to empower clinical trials in the immuno-oncology (IO) space. , IO therapies ...
(Date:9/13/2018)... ... September 13, 2018 , ... Asymmetrex’s director, James ... would have gotten in medicine, if we didn’t have the means to measure the ... patients?” His answer, “Nowhere! And that is what’s holding up progress in stem ...
Breaking Biology Technology:
Cached News: